Myriad Genetics | MYGN - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Agilent USD 946M 44M 2025-12
Becton, Dickinson and Co. USD 2.41B 1.72B 2025-12
Bio-Rad Laboratories USD 343.4M 1.9M 2025-09
Bruker USD 449.2M 69.8M 2025-12
Danaher USD 3.59B 375M 2026-03
Illumina USD 759M 26M 2025-12
J&J USD 17.24B 642M 2026-03
Mettler Toledo International USD 675.44M 65.98M 2025-12
Myriad Genetics USD 146.8M 3M 2025-12
OraSure Technologies USD 11.34M 435K 2025-12
Pacific Biosciences Of California USD 15.74M 601K 2025-12
Quest Diagnostics USD 906M 33M 2026-03
Quidel USD 274.8M 1.01B 2025-12
Repligen USD 103.83M 3.32M 2025-12
Revvity USD 421.66M 47.06M 2025-12
Standard Biotools USD 11.38M 1.9M 2025-12
Thermo Fisher Scientific USD 4.49B 146M 2026-03
Veracyte USD 101.97M 10.69M 2025-12
Waters USD 557.42M 97.44M 2025-12